Carl Zeiss Meditec AG

Carl Zeiss Meditec closes first nine months of 2023/24 with slight decline in revenue

Carl Zeiss Meditec AG: Revenue and EBIT forecast for fiscal year 2023/24 reduced amid slower than expected recovery of equipment business

Carl Zeiss Meditec closes first six months 2023/24 with a slight decline in revenue due to currency effects

Carl Zeiss Meditec AG: Release according to Article 111c of the AktG [the German Stock Corporation Act] with the objective of Europe-wide distribution

Carl Zeiss Meditec AG: Korrektur: Bekanntmachung der Einberufung zur Hauptversammlung am 21.03.2024 in Jena mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG

Carl Zeiss Meditec achieves slight revenue growth in first quarter of 2023/24

Carl Zeiss Meditec AG: Bekanntmachung der Einberufung zur Hauptversammlung am 21.03.2024 in Jena mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG

Carl Zeiss Meditec AG agrees to launch share buyback program with volume of up to €150m

U.S. FDA Approves the VISUMAX 800 with SMILE pro software from ZEISS

Carl Zeiss Meditec AG announces agreement to acquire Dutch Ophthalmic Research Center (D.O.R.C.)

Carl Zeiss Meditec AG announces agreement to acquire D.O.R.C.

Carl Zeiss Meditec increased revenue in fiscal year 2022/23 by around 10 percent

Carl Zeiss Meditec achieves further strong revenue growth after nine months of fiscal year 2022/23 with continued high strategic investments

Carl Zeiss Meditec achieves double-digit growth in first half year of 2022/23 with declining earnings

Forecast for fiscal year 2022/23 refined – Targeting widened and reduced range for EBIT margin – Further growth with reduced earnings in first half year of 2022/23

Carl Zeiss Meditec AG: Bekanntmachung der Einberufung zur Hauptversammlung am 22.03.2023 in Jena mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG

Carl Zeiss Meditec achieves further revenue growth in Q1 2022/23 – Orders on hand remain high

Carl Zeiss Meditec AG: Bekanntmachung der Einberufung zur Hauptversammlung am 22.03.2023 in Weimar mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG

Carl Zeiss Meditec remains on growth course in fiscal year 2021/22

Carl Zeiss Meditec achieves further significant growth in revenue and order intake after nine months of 2021/22